Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)

Author(s): Ernest Nadal, MD, PhD1,2; Delvys Rodríguez-Abreu, MD3; Marta Simó, MD, PhD4; Bartomeu Massutí, MD, PhD5; Oscar Juan, MD, PhD6; Gerardo Huidobro, MD7; Rafael López, MD8; Javier De Castro, MD, PhD9; Anna Estival, MD, PhD10; Joaquín Mosquera, MD11; Ivana Sullivan, MD, PhD12; Enriqueta Felip, MD, PhD13; Ana Blasco, MD14; Maria Guirado, MD15; Eva Pereira, BoS16; Noelia Vilariño, MD1,2,4; Valentín Navarro, PhD1; and Jordi Bruna, MD, PhD4
Source: DOI: 10.1200/JCO.22.02561 Journal of Clinical Oncology 41, no. 28 (October 01, 2023) 4478-4485

Dr. Anjan Patel's Thoughts

A nicely done Spanish study showing that in metastatic NSCLC, asymptomatic patients with brain metastases can have radiation therapy deferred.

Starting with systemic therapy was found to be reasonable and effective, validating a common practice. Patients were treated with atezolizumab + carboplatin + pemetrexed + steroids, and any number of brain mets was allowed as long as they had at least one 10mm in size or greater. This study excluded patients harboring EGFR/ALK driver mutations.

PURPOSE

The Atezo-Brain study evaluated atezolizumab combined with chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC) with untreated brain metastases, a population traditionally excluded from trials.

METHODS

This single-arm phase II clinical trial enrolled patients with advanced nonsquamous NSCLC with untreated brain metastases without neurologic symptoms or asymptomatic with medical treatment. Dexamethasone was allowed up to 4 mg once daily. Atezolizumab plus carboplatin and pemetrexed was given for four to six cycles followed by atezolizumab plus pemetrexed until progression for a maximum of 2 years. The primary end points were to determine the progression-free survival (PFS) rate at 12 weeks and the incidence of grade ≥3 adverse events during the first 9 weeks. Intracranial outcomes were assessed using response assessment in neuro-oncology brain metastases criteria.

RESULTS

Forty patients were enrolled and 22 (55%) were receiving corticosteroids at baseline. The overall 12-week PFS rate was 62.2% (95% credibility interval [CrI], 47.1 to 76.2). The rate of grade 3/4 adverse events during the first 9 weeks was 27.5%. Most neurologic events were grade 1 and 2 but five patients (12.5%) experienced grade 3-4 neurologic events. With a median follow-up of 31 months, intracranial median PFS was 6.9 months and response rate was 42.7% (95% CrI, 28.1 to 57.9). Systemic median PFS was 8.9 months and response rate was 45% (95% CrI, 28.1 to 57.9). The median overall survival (OS) was 11.8 months (95% CI, 7.6 to 16.9) and the 2-year OS rate was 27.5% (95% CI, 16.6 to 45.5).

CONCLUSION

Atezolizumab plus carboplatin and pemetrexed demonstrates activity in patients with advanced nonsquamous NSCLC with untreated brain metastases with an acceptable safety profile.

Author Affiliations

1Department of Medical Oncology, Institut Català d’Oncologia (ICO), L’Hospitalet de Llobregat, Barcelona, Spain; 2Preclinical and Experimental Research in Thoracic Tumors (PReTT) Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain; 3Department of Medical Oncology, Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain; 4Neuro-Oncology Unit, Hospital Universitari de Bellvitge-ICO, IDIBELL, L’Hospitalet, Barcelona, Spain; 5Department of Medical Oncology, Hospital General de Alicante, Alicante, Spain; 6Department of Medical Oncology, Hospital Universitari La Fe, Valencia, Spain; 7Department of Medical Oncology, Complejo Hospitalario Universitario de Vigo, Vigo, Spain; 8Department of Medical Oncology, Hospital Clínico de Valladolid, Valladolid, Spain; 9Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain; 10Department of Medical Oncology, Institut Català d’Oncologia (ICO), Badalona, Spain; 11Department of Medical Oncology, Hospital Universitario A Coruña, A Coruña, Spain; 12Department of Medical Oncology, Hospital Sant Pau, Barcelona, Spain; 13Department of Medical Oncology, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology, Barcelona, Spain; 14Department of Medical Oncology, Hospital General de Valencia, Valencia, Spain; 15Department of Medical Oncology, Hospital Universitario de Elche, Elche, Spain; 16Spanish Lung Cancer Group, Barcelona, Spain

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence?

Very thought-provoking review of immune checkpoint blockade therapy and strategies to possibly de-escalate therapy in the future. Could we reduce doses, extend dose intervals or diminish the duration of treatment? There is some (low-level) data supporting these ideas. However, ongoing prospective studies, mostly being done in countries with nationalized systems, will be informative on these topics. Expect interest in this topic to increase in a couple of years.

Read More »